Osimertinib for an older de novo T790M patient with chronic kidney disease
Hideyasu Yamada
Hitachinaka Medical Education and Research Center, University of Tsukuba Hospital, Hitachinaka-shi, Japan
Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Department of Respiratory Medicine, Hitachi Ltd, Hitachinaka General Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorHiroaki Satoh
Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Division of Respiratory Medicine, Mito Medical Center, Mito, Japan
Search for more papers by this authorNorihito Hida
Department of Respiratory Medicine, Hitachi Ltd, Hitachinaka General Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorTaisuke Nakaizumi
Department of Respiratory Medicine, Hitachi Ltd, Hitachinaka General Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorHideo Terashima
Hitachinaka Medical Education and Research Center, University of Tsukuba Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorNobuyuki Hizawa
Division of Respiratory Medicine, Mito Medical Center, Mito, Japan
Search for more papers by this authorHideyasu Yamada
Hitachinaka Medical Education and Research Center, University of Tsukuba Hospital, Hitachinaka-shi, Japan
Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Department of Respiratory Medicine, Hitachi Ltd, Hitachinaka General Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorHiroaki Satoh
Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Division of Respiratory Medicine, Mito Medical Center, Mito, Japan
Search for more papers by this authorNorihito Hida
Department of Respiratory Medicine, Hitachi Ltd, Hitachinaka General Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorTaisuke Nakaizumi
Department of Respiratory Medicine, Hitachi Ltd, Hitachinaka General Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorHideo Terashima
Hitachinaka Medical Education and Research Center, University of Tsukuba Hospital, Hitachinaka-shi, Japan
Search for more papers by this authorNobuyuki Hizawa
Division of Respiratory Medicine, Mito Medical Center, Mito, Japan
Search for more papers by this author
References
- 1Mok TS, Wu Y-L, Ahn M-J et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.
- 2Santarpia M, Liguori A, Karachaliou N et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 2017; 8: 109–125.
- 3Saxena A, Nagasaka M, Li Z, Becker DJ, Levy BP. Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer. Oncology (Williston Park) 2014; 28: 526, 528, 530, 534.
- 4Dickinson PA, Cantarini MV, Collier J et al. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 2016; 44: 1201–1212.
